深圳信隆健康产业发展股份有限公司 2023 年度监事会工作报告 一、监事会工作情况 报告期内，监事会严格按照《公司法》、《公司章程》、《监事会议事规则》和有关法律、 法规所赋予的职责和要求，以切实维护公司利益和全体股东权益出发，诚信积极勤勉为原则， 独立认真履行监督职责，通过实地调研和列席、出席董事会、股东大会，了解和掌握公司的 经营决策、投资方案、生产经营情况，对公司董事、总经理和其他高级管理人员的尽职尽责 情况进行了监督，维护了公司利益和全体股东的合法权益。 （一）报告期内，监事会成员列席了 8 次董事会会议。 （二）报告期内，各次股东大会均有监事出席。 报告期内，监事会认真履行《公司法》、《公司章程》等相关法律法规赋予的职权，积极 参加股东大会，列席董事会会议，对公司 2023 年依法运作情况进行监督，认为：公司依照国 家有关法律法规、公司章程的规定以及股东大会、董事会的决议和授权规范运作，决策科学 合理，程序合法，法人治理结构和内部控制制度比较合理规范；公司董事、高级管理人员执 行职务时能够勤勉尽责，认真履行股东大会和董事会的决议，未发现违反法律法规、公司章 程或损害公司利益和股东合法权益的行为。对此 ...

深圳信隆健康产业发展股份有限公司 2024年日常关联交易计划公告 证券代码：002105 证券简称：信隆健康 公告编号：2024-011 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、日常关联交易基本情况 （一）日常关联交易概述 深圳信隆健康产业发展股份有限公司（以下简称"公司"）为应经营发展需要，公司预计 2024年度将与信隆车料工业股份有限公司（以下简称"台湾信隆"）、艾跃炫贸易（上海）有 限公司（以下简称"艾跃炫"）发生销售产品、采购商品的关联交易事项，预计2024年关联交 易总额不超过1,800万元，上年度公司与关联方发生的日常关联交易总额为609.30万元。公司 就2024年度拟与关联方之间开展的关联交易计划，编制了《深圳信隆健康产业发展股份有限公 司2024年度日常关联交易计划》，公司于2024年4月18日召开独立董事专门会议2024年第一次 会议，全体独立董事一致通过《关于<2024年度日常关联交易计划>的议案》并将《深圳信隆健 康产业发展股份有限公司2024年度日常关联交易计划》提请公司2024年4月22日召开的第七届 董事会第八次会议审 ...

证券代码：002105 证券简称：信隆健康 公告编号： 2024-013 公司将在 2023 年年度报告网上说明会上，在信息披露允许的范围内对投资者普遍 关注的问题进行回答。活动交流期间，投资者仍可登陆活动界面进行互动提问。 深圳信隆健康产业发展股份有限公司 关于 2023 年年度报告网上说明会公开征集问题的 提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 深圳信隆健康产业发展股份有限公司(以下简称"公司")已于 2024 年 4 月 24 日发 布了公司《2023 年年度报告》并于同日披露了《关于举办 2023 年年度报告网上业绩说 明会的公告》。公司将于 2024 年 5 月 17 日（星期五）下午 15:00-17:00 在全景网"投 资者关系互动平台"http://irm.p5w.net 举行 2023 年年度报告网上说明会。 为充分尊重投资者，提升交流的针对性，现就公司 2023 年年度报告网上说明会提 前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2024 年 5 月 14 日 17:00 前访问 https://ir ...

证券代码：002105 证券简称：信隆健康 公告编号：2024-012 深圳信隆健康产业发展股份有限公司 关于举行2023年年度报告网上说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 深圳信隆健康产业发展股份有限公司（以下简称：公司）将于2024年5月17日（星期五）下午 15:00-17:00 在全景网"投资者关系互动平台"举行2023年年度报告网上说明会，本次说明会将 采用网络远程方式举行，投资者可登陆投资者互动平台：http://irm.p5w.net 参与本次说明会。 公司出席本次说明会的人员有：公司董事长廖学金先生、董事会秘书陈丽秋女士、财务总监 邱东华先生、独立董事高海军先生。 欢迎广大投资者积极参与！ 特此公告。 深圳信隆健康产业发展股份有限公司董事会 2024年4月24日 ...

2024 年 4 月 22 日 董事会关于独立董事独立性自查情况的专项意见 根据中国证券监督管理委员会《上市公司独立董事管理办法》《深圳证券交易所股票上市 规则》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等要求， 深圳信隆健康产业发展股份有限公司（以下简称"公司"）董事会，就公司在任独立董事高 海军先生、陈大路先生、王巍望女士、甘勇明先生的独立性情况进行评估并出具如下专项意 见： 经核查独立董事高海军先生、陈大路先生、王巍望女士、甘勇明先生的任职经历以及签 署的相关自查文件，上述人员未在公司担任除独立董事以外的任何职务，也未在公司主要股 东公司担任任何职务，与公司以及主要股东之间不存在利害关系或其他可能妨碍其进行独立 客观判断的关系，不存在影响独立董事独立性的情况，符合《上市公司独立董事管理办法》 《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》中对独立董事 独立性的相关要求。 深圳信隆健康产业发展股份有限公司 董事会 深圳信隆健康产业发展股份有限公司 ...

U.S. Bicycle Market Trends - The U.S. bicycle market faces high inventory levels in 2023 due to explosive consumption during 2020-2022, with sales weakened by interest rate hikes and high inflation. Brands are offering 30%-40% discounts to clear inventory, putting pressure on small and medium brands[30] - U.S. e-bike sales surpassed 1 million units in 2023, growing 25% YoY. The North American e-bike market is projected to reach $4.1 billion by 2028[36] European E-bike Market Trends - The European e-bike market is projected to reach 12 million units by 2030, with a shift towards leisure, short-distance commuting, and intelligent transportation. Traditional bicycle demand is declining sharply[31] - European e-bike market inventory remains high, with 30%-40% discounts offered. The UK reduced anti-dumping duties on Chinese e-bikes from 62.1% to 16.2%, with a total tax rate of 33.4%[37] Global E-bike Market Growth - The global e-bike market is expected to grow from $28.9 billion in 2023 to $52.6 billion by 2028, with a 12% CAGR. The e-cargo bike market reached $2.04 billion in 2023[35] Company Market Position and Competitors - The company holds 25% of the global bicycle control parts market and 15% of the suspension fork market, with main competitors being Suntour (70%) and RST (10%)[39] - Competitor SR has expanded production capacity in Germany and Taiwan, with 6 service centers in Germany, strengthening its local presence[41] Shared Mobility Challenges - The U.S. shared e-scooter market faces challenges, with Bird Global filing for bankruptcy in December 2023[42] - European e-scooter shipments declined 50%-70% in 2023, with Xiaomi reducing its annual budget by over 90%, cutting approximately 900,000 units[44] Shipping and Logistics - Red Sea shipping crisis caused container shipping rates to surge by nearly 600%, with rates for a 40-foot container exceeding $10,000[49] - Shanghai to US West Coast shipping rates rose 43.2% to $3,974/FEU, while Shanghai to US East Coast rates increased 47.9% to $5,813/FEU[50] - New FAK rates effective January 15 set 40-foot container rates at $5,000 for US West Coast and $7,000 for East Coast/Gulf ports[51] Shared Mobility Mergers and Market Leaders - Tier Mobility and Dott merger expected to create Europe's largest shared mobility operator with combined revenue exceeding €200 million[52][54] - Ninebot maintains China's top position in smart two-wheeled electric vehicles with leading sales in 4000+/5000+ RMB premium segments[56] - Ninebot's global electric scooter production surpassed 10 million units, with 2.3 million units sold in 2020, accounting for 85% of China's total production[59] Global Electric Scooter Market Forecast - QY Research forecasts global electric scooter production to reach 10.01 million units by 2027, with a market value of $3.34 billion[59] - Boston Consulting Group predicts global smart electric scooter market could reach $50 billion by 2025, with $15 billion in Europe/US and $8 billion in China[59] Micromobility Trends in Australia - Australia's micromobility market grew fivefold since 2017, with over 250,000 personal electric scooters in use[60] - 97% of Australian users find electric scooters more enjoyable than e-bikes, with 85% using them for leisure and 30% planning to increase usage[60] Electric Scooter Market in Russia - Electric scooter sales in Russia increased by 43% year-on-year, reaching 245,000 units in Q1 2023[62] - 85% of personal mobility vehicle purchases in Russia are electric scooters, with 10% being electric bicycles[62] - Shared electric scooter users in Russia aged 50+ increased by 84% over the past year[63] Elderly and Disabled Assistive Devices Market - The global elderly and disabled assistive devices market is projected to reach 299.31 billion yuan by 2030, with a CAGR of 9.11% from 2023[69] - North America holds the largest share of the global wheelchair market at 32.47% in 2023[69] - The Asia-Pacific region is the fastest-growing wheelchair market, expected to grow at a CAGR of 11.8% from 2023 to 2028[73] Rehabilitation Medical Device Market in China - China's rehabilitation medical device market is projected to reach 67 billion yuan by 2023, growing at a CAGR of 19.1%[74] - Global electric wheelchair retail sales are expected to reach 322.023 billion yuan in 2023, a 48.3% increase from 2022[75] - Smart electric wheelchair production is expected to reach 183.021 billion yuan in 2023, a 58.4% increase from 2022[75] - China's electric wheelchair production reached approximately 2.56 million units in 2022[75] Financial Performance and Revenue Decline - Total operating revenue decreased by 47.18% to RMB 963.92 million in 2023 compared to RMB 1.82 billion in 2022[90] - Bicycle parts revenue dropped by 55.47% to RMB 666.58 million, accounting for 69.15% of total revenue[90] - Sports and fitness rehabilitation equipment revenue decreased by 9.02% to RMB 283.47 million, making up 29.41% of total revenue[90] - Domestic sales accounted for 42.06% of total revenue, decreasing by 37.81% to RMB 405.39 million[90] Production and Sales Volume Decline - Bicycle parts sales volume fell by 54.47% to 2.01 million units, with production volume dropping by 58.82% to 1.78 million units[93] - Sports and fitness rehabilitation equipment sales volume decreased by 11.07% to 208,100 units, with production volume down by 5.98% to 195,100 units[93] Customer and Supplier Concentration - Top five customers contributed 35.15% of total sales, with the largest customer accounting for 16.54% of total revenue[99][100] - Top five suppliers accounted for 16.03% of total procurement, with the largest supplier contributing 3.61%[100] Subsidiary Establishment and R&D - The company established a new subsidiary, Shenzhen Laiqi Technology Co., Ltd., in October 2023 with a registered capital of RMB 10 million[98] - R&D expenses decreased by 19.44% to RMB 45.58 million in 2023 compared to RMB 56.58 million in 2022[102][104] - R&D personnel decreased by 13.25% to 406 in 2023 from 468 in 2022, with a slight increase in R&D personnel ratio to 16.76%[103] Cash Flow and Financial Activities - Operating cash flow decreased by 25.59% to RMB 274.81 million in 2023 from RMB 369.32 million in 2022[105] - Investment cash inflow surged by 2311.38% to RMB 58.79 million in 2023 due to the recovery of structured deposits[106] - Investment cash outflow increased by 112.83% to RMB 170.11 million in 2023, mainly due to increased cash expenditures on fixed assets[106] - Net cash flow from financing activities improved by 33.86% to a negative RMB 172.31 million in 2023[106] Profit and Non-Operating Income - Net profit was RMB 18.34 million, significantly lower than the operating cash flow of RMB 276.22 million, mainly due to reduced inventory and lower depreciation expenses[107] - Non-operating income reached RMB 24.15 million, accounting for 172.78% of total profit, primarily from temporary relocation fees[109] - Asset impairment losses amounted to RMB 6.49 million, accounting for 46.42% of total profit, mainly due to inventory obsolescence and idle fixed assets[109] - Government subsidies contributed RMB 1.60 million, accounting for 11.43% of total profit[109] Strategic Goals and Market Expansion - Revenue growth is the primary goal, with a focus on new product development and new customer acquisition[155] - Actively visiting overseas customers to develop new business opportunities[155] - Participating in domestic medical exhibitions to expand the domestic market[155] - Investing in the development of manual and electric wheelchair ODM products[155] - Developing proprietary ODM products, such as electric wheelchairs with lifting mechanisms[155] - Establishing a cost reduction project to meet customer pricing requirements[155] - Optimizing business and operational management processes to prepare for future growth[155] Export Sales and Tariff Impact - Direct export sales accounted for 64.28% of total sales in 2022[156] - Bicycle parts exports are indirectly affected by US tariffs but not by EU anti-dumping duties[156] Corporate Governance and Independence - The company has established a comprehensive internal audit system, with an internal audit institution reporting directly to the Board Audit Committee, ensuring independence and effectiveness in auditing internal controls and financial activities[170] - The company maintains complete independence in assets, personnel, finance, organization, and business operations, with no reliance on shareholders for production or business premises[172] - The company's personnel, including directors, supervisors, and senior management, are independently appointed and remunerated, with no overlap in roles with shareholders or related enterprises[173] - The company has an independent financial department established since 1991, adhering to the "Enterprise Accounting Standards" and maintaining separate bank accounts and tax filings[174] - The company operates independently in its core business of bicycle parts and sports fitness rehabilitation equipment, with no overlap in business activities with shareholders or related enterprises[175] Shareholder Meetings and Resolutions - The 2022 Annual General Meeting had a 51.17% investor participation rate, with key resolutions including the approval of the 2022 financial report and profit distribution plan[176] Executive Compensation - The company strictly adheres to the "Compensation System for Directors, Supervisors, and Senior Management," with actual compensation for 2023 approved by the Remuneration and Assessment Committee and disclosed in the 2023 annual report[199] - Each director/supervisor receives an annual remuneration of 120,000 RMB (after tax deduction), paid monthly, with taxes withheld by the company[199] - The remuneration for directors and supervisors was revised and approved at the 2022 first extraordinary general meeting, effective from May 2022[199]

证券代码：002105 证券简称：信隆健康 公告编号：2024-014 深圳信隆健康产业发展股份有限公司 关于召开2023年年度股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 经深圳信隆健康产业发展股份有限公司（以下简称"公司"）第七届董事会第八次会议决 议,公司定于2024年5月21日召开2023年年度股东大会，现将本次股东大会有关事项通知如下： 一、召开会议的基本情况 1、股东大会届次：2023年年度股东大会 2、股东大会的召集人：公司董事会 5、会议的召开方式：本次股东大会采取现场表决和网络投票相结合的方式召开。公司将 通过深圳证券交易所交易系统和互联网投票系统（http://wltp.cninfo.com.cn）向全体股东 提供网络形式的投票平台,在股权登记日登记在册的所有股东均可以在网络投票时间内通过上 述系统行使表决权，或参加现场股东大会行使表决权。公司股东应选择现场投票、网络投票中 的一种方式，如果同一表决权出现重复投票表决的，以第一次投票表决结果为准。 6、股权登记日：2024年5月14日 7、出席对象： （1）于股权登记日20 ...

深圳信隆健康产业发展股份有限公司 2023 年度利润分配预案的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导 性陈述或重大遗漏。 深圳信隆健康产业发展股份有限公司（以下简称"公司"）2024 年 4 月 18 日召开独立董 事专门会议 2024 年第一次会议，经审议，全体独立董事一致通过《深圳信隆健康产业发展股 份有限公司 2023 年度利润分配预案的议案》并取得了明确同意的意见。公司并于 2024 年 4 月 22 日召开第七届董事会第八次会议和第七届监事会第八次会议，审议通过了《深圳信隆健 康产业发展股份有限公司 2023 年度利润分配预案的议案》，本次利润分配预案尚需提交 2023 年度股东大会审议批准。现将相关事宜公告如下： 证券代码：002105 证券简称：信隆健康 公告编号： 2024-008 提取上述法定盈余公积金后，2023 年度公司可供股东分配的利润加上以前年度滚存未分 配利润，累积可供股东分配的利润为人民币 414,864,104.68 元。 2、2023 年度不提取任意盈余公积金。 3、以公司 2023 年 12 月 31 日股本 368,160,00 ...

证券代码：002105 证券简称：信隆健康 公告编号： 2024-007 深圳信隆健康产业发展股份有限公司 第七届监事会第八次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导 性陈述或重大遗漏。 一、监事会会议召开情况 深圳信隆健康产业发展股份有限公司（以下简称：公司）第七届监事会第八次会议通知于 2024 年 4 月 9 日以书面和电子邮件的方式发出，会议于 2024 年 4 月 22 日在公司办公楼 A 栋 2 楼会议室以现场方式召开，会议由监事莫红梅女士主持，会议应到监事 3 名，实际出席监事 2 名，监事会主席黄秀卿因出差原因，书面授权委托监事莫红梅代表出席并表决。本次会议符合 《中华人民共和国公司法》等法律、行政法规、部门规章、规范性文件和本公司《公司章程》 的规定。 二、监事会会议审议情况 会议讨论并通过了下列决议： （一）审议《深圳信隆健康产业发展股份有限公司 2023 年度监事会工作报告的议案》 表决结果: 3 票同意， 0 票弃权， 0 票反对。 （二）审议《深圳信隆健康产业发展股份有限公司 2023 年度财务决算报告的议案》 表决结果: 3 票同意 ...

本人作为深圳信隆健康产业发展股份有限公司（以下简称"公司"） 的独立董事，在任职期间能够严格按照《公司法》、《关于在上市公 司建立独立董事的指导意见》、《公司章程》、《公司独立董事制度》 等法律法规及相关制度的规定和要求，充分发挥独立董事的作用，恪 尽职守，勤勉尽责，维护了公司、公司股东尤其是中小股东的利益。 报告期内，本人能够勤勉地行使法律所赋予的权利，按时出席公司各 次相关会议，对有关议案或议题发表独立意见，切实履行了独立董事 的职责。现将2023年度我履行独立董事职责的具体情况汇报如下： 一、出席会议情况 作为独立董事，本人在召开董事会前主动了解并获取作出决策前 所需要的情况和资料，详细了解公司整个经营运作的情况，为董事会 的重要决策做了充分的准备工作。会议上，本人认真审议每个议案， 积极参与讨论并提出合理化建议，为公司董事会做出科学决策起到了 积极的作用。本人对提交董事会会议审议的相关议案均投了赞成票， 无反对、弃权的情况。 （二）列席股东大会的有关情况 报告期内，本人列席了4次股东大会。 深圳信隆健康产业发展股份有限公司 独立董事高海军 2023 年度述职报告 尊敬的各位股东： （一）出席董事会会议 ...